Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 6, 2023 00:01 UTC |
DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl
|
GrantRestricted Stock Unit · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020293 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 3,036 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 23:59 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantRestricted Stock Unit · Derivative | 11,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020292 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,629 Underlying: Common Stock · 11,648 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 23:57 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 7,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020291 · form4.xml · derivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,585 Underlying: Common Stock · 7,758 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 15:52 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 212 | $240.00 | $50,880.00 |
DisclosureSEC source: 0001127602-23-019686 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,604.6975 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 25.9383 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 12:24 UTC |
Rothman PaulDirector
|
GrantRestricted Stock Unit · Derivative | 642 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018221 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642 Underlying: Common Stock · 642 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on June 6, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on June 6, 2024. Read SEC document |
| May 19, 2023 Filed May 23, 2023 12:06 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionNon-qualified Stock Options · Derivative | 4,300 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-23-016525 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,300 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 19, 2023 Filed May 23, 2023 12:06 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
SaleCommon Stock | 4,300 | $216.91 | $932,706.98 |
DisclosureSEC source: 0001127602-23-016525 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,946 Read SEC document |
| May 19, 2023 Filed May 23, 2023 12:06 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 4,300 | $182.51 | $784,793.00 |
DisclosureSEC source: 0001127602-23-016525 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionNon-qualified Stock Options · Derivative | 1,500 | $0.00 Strike: $130.60 | $0.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,500 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
SaleCommon Stock | 1,500 | $216.77 | $325,155.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Exercise / conversionCommon Stock | 1,500 | $130.60 | $195,900.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,187.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantRestricted Stock Unit · Derivative | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015024 · form4.xml · derivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,121 Underlying: Common Stock · 440 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantNon-qualified Stock Options · Derivative | 1,400 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015024 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires 2033-05-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:44 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015023 · form4.xml · derivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981 Underlying: Common Stock · 300 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:44 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantNon-qualified Stock Options · Derivative | 1,000 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015023 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2033-05-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:43 UTC |
Bailey Megan D.EVP, Chief Strategy Officer
|
GrantNon-qualified Stock Options · Derivative | 600 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015022 · form4.xml · derivative · entry 2 Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2033-05-04 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:43 UTC |
Bailey Megan D.EVP, Chief Strategy Officer
|
GrantRestricted Stock Unit · Derivative | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015022 · form4.xml · derivative · entry 1 Bailey Megan D. · CIK 0001975682 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,807 Underlying: Common Stock · 180 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:41 UTC |
DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl
|
GrantRestricted Stock Unit · Derivative | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015021 · form4.xml · derivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,664 Underlying: Common Stock · 370 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:41 UTC |
DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl
|
GrantNon-qualified Stock Options · Derivative | 1,200 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015021 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2033-05-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:50 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantRestricted Stock Unit · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-012716 · form4.xml · derivative · entry 2 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 Underlying: Common Stock · 990 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:50 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $234.01 | $0.00 |
DisclosureSEC source: 0001127602-23-012716 · form4.xml · derivative · entry 1 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2033-04-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 14:05 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 3,897 | $225.81 | $879,981.57 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,687.4022 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:14 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 18,646 | $224.70 | $4,189,756.20 |
DisclosureSEC source: 0001127602-23-011751 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,888 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:14 UTC |
Schechter Adam HDirector · President & CEO
|
GrantCommon Stock | 42,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011751 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,534 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:13 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 2,886 | $224.70 | $648,484.20 |
DisclosureSEC source: 0001127602-23-011750 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,946 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:13 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantCommon Stock | 6,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011750 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,832 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:11 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 5,179 | $224.70 | $1,163,721.30 |
DisclosureSEC source: 0001127602-23-011749 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,176 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:11 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantCommon Stock | 11,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011749 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,355 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:09 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 2,990 | $224.70 | $671,853.00 |
DisclosureSEC source: 0001127602-23-011748 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,185.7624 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:09 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantCommon Stock | 6,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011748 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,175.7624 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:07 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 1,799 | $224.70 | $404,235.30 |
DisclosureSEC source: 0001127602-23-011747 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,878 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:07 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantCommon Stock | 4,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011747 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,677 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:05 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 2,866 | $224.70 | $643,990.20 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,584.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:05 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantCommon Stock | 6,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,450.4022 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:03 UTC |
Seltz Judith CEVP, CHRO
|
Tax withholdingCommon Stock | 1,164 | $224.70 | $261,550.80 |
DisclosureSEC source: 0001127602-23-011745 · form4.xml · nonDerivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,181.9485 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:03 UTC |
Seltz Judith CEVP, CHRO
|
GrantCommon Stock | 3,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011745 · form4.xml · nonDerivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,345.9485 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:56 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 1,269 | $224.70 | $285,144.30 |
DisclosureSEC source: 0001127602-23-011744 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,634 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:56 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantCommon Stock | 3,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011744 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,903 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:50 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 1,371 | $224.70 | $308,063.70 |
DisclosureSEC source: 0001127602-23-011743 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,790.7592 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:50 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantCommon Stock | 3,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011743 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,161.7592 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:49 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 526 | $224.70 | $118,192.20 |
DisclosureSEC source: 0001127602-23-011742 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,432.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:49 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantCommon Stock | 1,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011742 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,958.2194 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 13:04 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008977 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180 Underlying: Common Stock · 1,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units fully vested on March 2, 2023. F3 · derivative.expiration_date: The Restricted Stock Units fully vested on March 2, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 13:04 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 374 | $239.46 | $89,558.04 |
DisclosureSEC source: 0001127602-23-008977 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,669 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 13:04 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 1,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008977 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 14:54 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-23-006642 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Underlying: Common Stock · 3,000 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 14:54 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
SaleCommon Stock | 8,000 | $250.58 | $2,004,675.20 |
DisclosureSEC source: 0001127602-23-006642 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,069 F1 · price: The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 14:54 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 3,000 | $182.51 | $547,530.00 |
DisclosureSEC source: 0001127602-23-006642 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:51 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 309 | $247.63 | $76,517.67 |
DisclosureSEC source: 0001127602-23-005485 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 20:25 UTC |
BELINGARD JEAN-LUCDirector
|
Tax withholdingCommon Stock | 75 | $248.13 | $18,609.75 |
DisclosureSEC source: 0001127602-23-005114 · form4.xml · nonDerivative · entry 2 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,929 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.